|
|||||
|
|
Intravenous and intramuscular pharmacokinetics of recombinant leukocyte a interferon |
|
| Authors: | L. D. Bornemann H. E. Spiegel Z. E. Dziewanowska S. E. Krown W. A. Colburn |
| Affiliation: | (1) Department of Pharmacokinetics, Biopharmaceutics and Drug Metabolism, Hoffmann-La Roche Inc., Nutley, N.J., USA;(2) Department of Clinical Laboratory Research, Hoffmann-La Roche Inc., Nutley, N.J., USA;(3) Department of Medical Research I, Hoffmann-La Roche Inc., Nutley, N.J., USA;(4) Memorial Sloan-Kettering Cancer Center, New York, N.Y., USA |
| Abstract: | Summary Interferon is currently being evaluated for the treatment of disseminated cancer and viral diseases. Alpha interferons have shown to be effective in the treatment of a number of malignancies. Recombinant leukocyte A interferon (rIFN- A) is an alpha interferon produced by recombinant DNA techniques. A kinetic evaluation of rIFN-A following intravenous and intramuscular administration has not been adequately defined. The present study was designed to evaluate the kinetics of rIFN-A following intravenous and intramuscular administration of 3, 9 or 18×106 units to patients with disseminated cancer.A preliminary report of this study was presented at the meeting of the American Society for Clinical Pharmacology and Therapeutics in San Diego, March 1983 (1). |
| Keywords: | interferon cancer patients recombinant leukocyte A interferon rIFN- |
| 本文献已被 SpringerLink 等数据库收录！ | |